MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Sensyne Health strikes Covid-19 testing deal with Excalibur

StockMarketWire.com

Sensyne Health has licenced its MagnifEye technology to Excalibur Healthcare Services for use with lateral flow diagnostic tests, including Covid-19.

The MagnifEye system is a smartphone and a web-based app that uses a cloud-based deep learning algorithm to analyse lateral flow tests.

The initial focus will be on use of MagnifEye for Covid-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer and other disease conditions that Excalibur is currently developing.

The Excalibur Covid-19 antigen lateral flow diagnostic test has been approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.

Paul Drayson, chief executive of Sensyne Health, said: The combination of Sensyne's clinical AI technology and Excalibur's test will, we believe, provide the most accurate diagnostic lateral flow test available in the world today.

'This agreement reflects the UK's leadership position and expertise in life science and data science and underlines Sensyne's expertise in putting the AI inside a growing range of innovations.

At 1:58pm: (LON:SENS) Sensyne Health Plc Ord 10p share price was 0p at 119p


Story provided by StockMarketWire.com